TKNOAlpha Teknova, Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is TKNO?
Alpha Teknova, Inc. earns −21% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 30 points below what the capital costs: growth destroys value
- Operating margin
- −36%
Operating margin · Drug Manufacturers - Specialty & Generic median 9.5% · 12 months to Q2 2026
- Share count, year on year
- +0.35%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 5.1%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | 15% |
| FY2021 | −33% |
| FY2022 | −120% |
| FY2023 | −97% |
| FY2024 | −69% |
| FY2025 | −42% |
Details›
- Gross margin12 months to Q2 2026
- 35%
- Operating margin12 months to Q2 2026
- −36%
- Net margin12 months to Q2 2026
- −38%
- Free cash flow margin
- −17%
- R&D as % of revenue
- 5.1%
- Revenue, trailing twelve months
- $44M
- Free cash flow, trailing twelve months
- −$7.4M
- Net income, trailing twelve months
- −$17M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −21%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from TKNO and who it buys from, as the companies report it.
- Distributor customer A21%
Share of revenue · FY2025 10-K
- One distributor38%
Share of purchases · FY2025 10-K
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; TKNO’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.
Drug Manufacturers, Specialty & Generic
Ranks #24 of 39 by RyuScore